Antibiotics for treatment of bronchiectasis exacerbations in children - The Bronchiectasis Exacerbation Study (Study 2).

Conditions

None listed

Brief summary

Our national study aims to improve the management of bronchiectasis in children, a lung condition that is common in Indigenous people worldwide, and also occurs in non-Indigenous people. This study aims to discover whether treating respiratory exacerbations with one of two different oral antibiotics is more effective at resolving the exacerbation. The results of this study will impact on national and international guidelines and substantially advance knowledge on exacerbations of childhood bronchiectasis.

Goyal V, Yerkovich ST, Grimwood K, Marchant JM, Byrnes CA, Masters IB, Chang AB.

2023-07-10

10.1016/j.chest.2023.07.002

Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial.

Goyal V, Grimwood K, Byrnes CA, Morris PS, Masters IB, Ware RS, McCallum GB, Binks MJ, Marchant JM, van Asperen P, O'Grady KF, Champion A, Buntain HM, Petsky H, Torzillo PJ, Chang AB.

2018-09-1843 citations

10.1016/s0140-6736(18)31723-9

Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): Study protocol for a randomized controlled trial

Anne B. Chang, Keith Grimwood, Andrew Wilson, Peter P Van Asperen, Catherine A. Byrnes et al. (16 authors)

Minerva Access (University of Melbourne)2017-08-2518 citations

10.1186/1745-6215-14-53

Interventions

Arm 1: Daily oral Azithromycin 5mg/kg for 21 days Arm 2: Twice daily oral Amoxycillin-Clavulanic Acid 22.5mg/kg for 21 days These treatments are administered at the onset of respiratory exacerbation after enrolment, and are administered only for one respiratory exacerbation.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

All

Age

0 to 19 Years

Healthy volunteers

No

Inclusion criteria

Aged less than 18 years. Bronchiectasis, as defined by HRCT scan within the last 5-years OR followed by a respiratory physician for treatment of bronchiectasis if diagnosed earlier. 2 or more respiratory exacerbations of bronchiectasis symptoms in the last 18 months prior to study enrolment.

Exclusion criteria

Cystic Fibrosis (sweat chloride >35mmol/L or gene mutation). Liver dysfunction. Severe (hypoxic, dyspnoea or hospitalisation required) or recent exacerbation (in the last 4 weeks prior to study enrollment. Known hypersensitivity to macrolides or penicillins. Taking regular maintenance antibiotics of the same class as the investigational antibiotics (macrolides and penicillins), or has taken macrolides or penicillins within 3 weeks of study enrolment. Current or recent (within 4 months prior to study enrolment) identification of pseudomonas organism in the airways. Current treatment for an oncology condition of any kind.

Outcome results